PhD student
University of Toronto, Canada
Chukwunonso Nwabufo is the founder of OneDrug and a multiple award-winning pharmaceutical Scientist with over five years' experience in drug development across academia and the pharmaceutical industry. Chuk is currently investigating strategies for improving the clinical efficacy and safety profile of COVID-19 drugs. In addition to receiving the prestigious Canadian Institutes of Health Research Award to support his doctoral research at the Leslie Dan Faculty of Pharmacy, Chuk has received over 20 awards and recognitions worth more than 100K C$ in funding for research, academic, and leadership accomplishments. Prior to joining the University of Toronto, Chuk worked for over 2 years at Gilead Sciences where he contributed to the development of Remdesivir for the treatment of severe COVID-19, as well as the development of a long-acting antiretroviral drug to improve medication adherence for HIV patients. During his Master’s program in Pharmacy at the University of Saskatchewan, his research was focused on the preclinical development of novel drugs for Parkinson’s disease. Chuk completed a BSc in Biochemistry, MSc in Pharmacy, and MBA, all with distinction. Chuk has authored 10 peer-reviewed scientific papers and 11 industry-standard peer-reviewed reports in support of drug development programs. Currently, Chuk serves as an Editorial board member of Drug Metabolism Reviews and Secretary for the Pharmacokinetic, Pharmacodynamic and Drug Metabolism Community of the American Association of Pharmaceutical Scientists, USA.